Search
Menu
Home
Sources
About
Contacts
EVT-101
EVT-101
, also known as
ENS-101
, is an
experimental
medication
which originated from
Roche
and is
under development
by
Evotec
AG
for the
treatment
of
major depressive disorder
. It acts as a
selective
NMDA receptor
subunit 2B
antagonist
. As of
November 2017
, EVT-101 is
in phase
II
clinical trials
for major
depressive disorder
, although no
recent
reports
of
development
have been
identified
. The
drug
was first
claimed
by Roche in
2002
.
